With a 15% bulk discount on orders of five or more vials, the per-vial cost drops to $114.75 a total saving of about $101 on a five-vial order
10 H 17 N 3 O 6 S Research or further manufacturing use only, not for food or drug use
GLP-1 7-36 is a 30 amino acid peptide derived from the proglucagon molecule that is synthesised in intestinal L cells, as well as in alpha cells of the pancreas and in neuronal clusters of the central nervous system (CNS).2 It is a peptide with a short half-life (23 min), due to rapid renal clearance and degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which converts GLP-1 into GLP-1 9-36, a form that does not interact with the GLP-1 receptor.1 The GLP-1 receptor (GLP-1R) belongs to the class B G protein-coupled glucagon receptor family.2,3 Activation of the Gs subunit leads to stimulation of adenylate cyclase, synthesis of cyclic AMP, mobilisation of intracellular calcium, and glucose-dependent insulin release by pancreatic beta cells.2,3 Intracellular signalling also involves various additional pathways, such as recruitment of beta-arrestin-1, which modulates receptor internalisation and desensitisation, as well as the effects of certain GLP-1R agonists.3,4 Depending on the structure of the ligand, intracellular signalling pathways are modulated towards cyclic AMP generation, activation of kinase cascades (ERK), and beta-arrestin-1 recruitment, all of which influence the biological effect and desensitisation of the GLP-1 receptor.4 Some GLP-1R agonists exhibit biased agonism, favouring intracellular activation of cyclic AMP with reduced beta-arrestin recruitment, which results in less GLP-1R desensitisation and a more prolonged biological action (Table 1)
Incretins: their physiology and application in the treatment of diabetes mellitus
Two faces of one seed: hormonal regulation of dormancy and germination
Diabetes and Metabolic Disorders: Changes in DPP-4 expression and/or activity are linked to metabolic disorders such as obesity and diabetes [5]
